CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...
SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio.
The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains.
Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China.
Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4 + T cell (CD4 + CER-T cell) with a chimeric antigen receptor CD8 + T cell (CD8 + CAR-T cell) or T cell receptor CD8 + T cell (CD8 + TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States.
With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally.
Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.'
About CERo Therapeutics Holdings, Inc.
CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies.
This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management.
Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Researchers swapped human recruiters for AI agents. AI did the job better, with a few drawbacks.
Some job seekers might be better off chatting with a bot. A new study found that applicants interviewed by an AI voice agent were 12% more likely to get a job offer than those screened by human recruiters. They were also more likely to actually start work and stick around after 30 days. The professional recruiters had bet on themselves in this hiring experiment. The AI proved them wrong. The study also found that when given the choice, 78% of applicants picked the AI interviewer over a human recruiter. Brian Jabarian, an economist at the University of Chicago Booth School of Business, and Luca Henkel, a behavioral economist at Erasmus University Rotterdam, partnered with global recruitment firm PSG Global Solutions to pit AI against human recruiters in a large-scale hiring experiment. The trial covered more than 70,000 applicants vying for entry-level customer service roles across 48 job postings in the Philippines. The jobs were with 23 Fortune 500 companies and 20 European firms. Applicants were randomly assigned to one of three interview conditions: a human recruiter, an AI recruiter, or a choice between the two. In all cases, human recruiters ultimately made the hiring decision after reviewing transcripts and a standardized test of language and analytical skills. That design allowed the researchers to isolate one variable: the interview conversation. Both humans and the AI followed the same interview guide. It started with eligibility questions, moved into career goals and work experience, and ended with job details. But the outcomes diverged. Why AI did better Applicants interviewed by AI recruiters received job offers in 9.73% of cases, compared to 8.7% under human recruiters. The study also found that they were 18% more likely to start work and 17% more likely to still be employed after 30 days. Using natural language processing, the researchers found that AI interviews were more structured, covered more topics, and encouraged richer answers. AI-led interviews drew out the kinds of cues that human recruiters usually reward — like conversational depth — while minimizing weaker signals, such as filler responses or irrelevant questions. Recruiters who reviewed the transcripts scored AI-interviewed candidates higher than those they interviewed themselves. "AI-led interviews elicited more hiring-relevant information," Jabarian and Henkel wrote, adding that applicants also reported similar levels of satisfaction with AI recruiters compared to humans. But the system wasn't perfect. About 5% of applicants ended their interviews once they realized they were speaking to AI, and in 7% of cases, the agent encountered technical issues. Applicants also rated the interaction as less "natural" than talking to a human. Jabarian and Henkel did not respond to a request for comment from Business Insider. How AI is changing hiring AI has been increasingly used in the job-seeking and hiring process. Candidates are leaning on it to help tailor their résumés, while employers use it to sift through the thousands of applications they receive. Emily DeJeu, an assistant professor at Carnegie Mellon University's Tepper School of Business who specializes in AI communication and etiquette, told Business Insider in May that AI-powered video interviews are likely to become more common as companies seek to streamline and automate early hiring stages. Any time technology promises to save time and money and make everything faster, "we by default pursue it — there's a kind of inevitability to it," she said. Tech investors said AI may upend recruiting. Victor Lazarte, a former general partner at Benchmark, said on an episode of the "Twenty Minute VC" podcast published in April that recruiters should be especially nervous about AI replacing their jobs. He said AI models would soon be better than people at interviewing candidates — and far more efficient than companies' messy, manual hiring processes. But not everyone is sold. In a Business Insider report published Monday, hiring managers said they are flooded with applications, many of them AI-optimized to seem like a perfect fit, while hundreds of frustrated job seekers reported thousands of unsuccessful applications. AI has made hiring a "cat and mouse game" between candidates and employers, as both use technology to try to suss out the other, said Hatim Rahman, an associate professor of management and organizations at Northwestern University. As a result, there's a push toward finding "more human signals in both the process of searching and applying," he added.
Yahoo
2 hours ago
- Yahoo
MBX Biosciences Submits IND for Once-Monthly Obesity Drug
MBX Biosciences Inc. (NASDAQ:MBX) is one of the best IPO stocks to buy according to Wall Street analysts. On June 16, MBX Biosciences announced the submission of an Investigational New Drug/IND application to the US FDA for MBX 4291. This drug is a long-acting GLP-1/GIP receptor co-agonist prodrug being developed for the treatment of obesity. The company's President and CEO, Kent Hawryluk, stated that MBX 4291 is designed to be a potential once-monthly injectable, which could offer less frequent dosing and improved gastrointestinal tolerability, potentially leading to better patient adherence and increased weight loss. MBX 4291 was created using the company's proprietary Precision Endocrine Peptide/PEP platform. A doctor holding a test tube of the biopharmaceutical company's NicAlert drug product while providing patient care. In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, a weekly GLP-1/GIP co-agonist that is already approved. Furthermore, these preclinical studies showed an extended duration of action for MBX 4291's active component compared to tirzepatide, supporting the potential for once-monthly administration. MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders. While we acknowledge the potential of MBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
2 hours ago
- CNBC
How tourists are weathering geopolitical uncertainty, currency moves and extreme heat
Geopolitics, currency moves and extreme weather are increasingly playing into tourists' considerations for their next vacation and affecting classic holiday destinations. Staple European spots France, Spain and Croatia, for example, have been facing record-breaking heat in recent weeks, which triggered wildfires in some locations. Conflict in the Middle East has meanwhile meant that tourists in nearby Cyprus were able to see missiles and smoke in the sky from the beach. Sluggish economic growth and inflationary fears, largely linked to U.S. President Donald Trump's tariff policies, appear to be making consumers more cautious with their spending. A weaker U.S. dollar has also diminished the currency's purchasing power abroad, with a June report from the European Travel Commission showing that high travel costs, alongside the current global perception of the U.S., have been weighing on voyage plans. "For American travellers, a weaker dollar has fuelled demand for countries where their purchasing power goes further, from parts of Latin America to Southeast Asia. Many are opting for package deals that lock in rates upfront, effectively turning travel planning into a smart financial strategy," Nicholas Smith, holidays digital director at Thomas Cook and the eSky Group online travel agency, told CNBC by email. Travelers also appear to be thinking twice before picking the U.S. as a destination amid political tensions and an increase in reports of tourists being detained or interrogated as they enter or leave the country. Linda Jonczyk, a spokesperson for Europe's largest tour operator TUI, said that there has been "some decline" in bookings for travel to the U.S. Earlier this month, TUI CEO Sebastian Ebel reportedly attributed the pullback to factors including reports of tourists facing border control issues. Elsewhere, Europe remains a key destination, despite challenges. Smith said the British pound to euro conversion rate has remained relatively stable, and the familiarity many tourists have with mainland Europe works in the region's favor. "Greece and Turkey also remain firm favourites, even with seasonal wildfire headlines, thanks to their compelling mix of history, hospitality, and value for money," he said. But, Smith also noted that "Turkey has found itself in a slightly tricky predicament. Inflation has pushed up prices, however as most people book all inclusive, it is somewhat mitigated." Still, there has been a growing trend of consumers swapping heat for cooler destinations as part of so-called "coolcations," Smith said. This includes travelers now turning to countries such as Iceland, Norway and Poland. TUI's Jonczyk meanwhile noted that the company's business is becoming less seasonally focused as it responds to "more of our customers preferring to travel outside the peak summer season as weather patterns especially around the Mediterranean change." According to Thomas Cook's Smith, "holidaymakers in 2025 are factoring in more elements than ever when choosing where to go - from currency movements and visa rules to climate patterns and unique cultural draws." "Travellers are becoming more intentional," he added, noting that tourists are seeking out spots that suit them and their priorities, rather than simply avoiding certain locations. Europe's wildfires are an especially big concern among travelers right now, travel experts said, after heatwaves triggered outbreaks in tourist hotspots including Spain, Portugal and Greece. Flames are still spreading in some locations. Over the weekend, Spanish infrastructure such as roads and train services was impacted, as Madrid deployed military emergency troops to try and constrain the fires, Reuters reported. Fires are also continuing to rage in neighboring Portugal, which last week requested assistance from the European Union and was forced to evacuate residents in some regions. In emailed comments, Portugal's tourism office meanwhile told CNBC that the country "remains a safe, welcoming, and fully operational destination for travelers," and that visitors were being hosted "as planned." Local tourism infrastructure was prepared for challenges like wildfires, they added. Rhys Jones, a travel insurance specialist at GoCompare, told CNBC that the price comparison website has increasingly been receiving inquiries about what how to handle traveling in an area were wildfires raged at one point, or if there's a risk of blazes. "The first thing we recommend doing is checking whether the Foreign Office has deemed your destination safe to travel to," Jones told CNBC by email. "If the Foreign Office says it isn't safe, then it's important you take this advice seriously. If you decide to travel regardless of the warnings and need to claim for something that happens during the trip, your travel insurer could refuse your claim," Jones said. On the flipside, insurers might not pay out if you choose to stay at home despite the Foreign Office saying it is safe to travel and there are no reported issues with flights or accommodation, he added. Jo Rhodes, a travel specialist at U.K. consumer group Which?, echoed this advice. "Holidaymakers should wait until closer to the departure date to see if the holiday can go ahead or what flexible booking options are offered from the tour operator or airline. Travel companies will be prioritising anyone due to depart in the next couple of days," Rhodes told CNBC by email.
